Thuli Gasa appointed head of corporate services at Dunlop Tyres South Africa
Dunlop Tyres SA CEO, Lubin Ozoux, said: 'We are extremely excited to announce Thuli's appointment as head of corporate services. She has been an invaluable member of the Dunlop team for many years, driving excellence in her roles as original equipment quality auditor, associate risk manager and strategic initiatives manager. We are fully confident that, empowered in this new role, she will continue to lead with exceptional dedication and professionalism to support Dunlop's growth.'
Gasa, who grew up in uMnambithi (formerly known as Ladysmith), began her journey with the company in 2016 as a quality auditor working with Original Equipment (OE) Manufacturers - key business partners for Dunlop. Gasa had to ensure Dunlop tyres met the specifications of the manufacturers, working closely with various teams on the factory floor.
In her new role, Gasa will be working alongside two internal audit managers and an HSE manager. Her key priorities include managing business risks, strengthening internal controls on high-risk processes, driving stringent health and safety standards, standardising operations across the company, managing risk critical utilities (water and energy supply), resetting the safety culture, and overseeing transformation in terms of B-EE across the company.
'In this role, I will continue to build on my previous functions, communicating between the different levels in the company, bringing insights from the factory floor to strategic decision-making. It's important to me to ensure that we work as one organisation, focused on proactively managing risks and delivering the best quality product for South Africans,' she said.
Gasa's personal journey is equally inspiring. Growing up in Ladysmith, where Dunlop is a major employer, she understands the importance of hard work, dedication and being a role model to young girls.
'Coming from Ladysmith, a little town in northern KZN, where there aren't many major employers, Dunlop's presence is extremely important for the town's success. That's why my role is very important to me – not only do I hope I want show that hard work pays off and you can reach your goals, but in my role, I aim to make a difference to my community and be an inspiration to the next generation. We often hear people say, 'life is not fair' we need to look beyond unfairness to find opportunities available for learning and self-development."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
30 minutes ago
- Zawya
New Absa–BYD partnership targets EV finance growth in South Africa
Absa and Chinese electric vehicle manufacturer BYD have signed a partnership agreement to expand green vehicle finance solutions in South Africa, targeting both retail customers and motor dealers. The move follows increased demand for new energy vehicles (NEVs) amid rising sustainability concerns. The deal was formalised at BYD's offices in Sandton, where representatives from both organisations outlined plans to establish a full-scale green vehicle finance ecosystem. Full-service financing for EV rollout Under the agreement, Absa will offer a suite of banking and financial services to BYD dealers and customers, including OEM and dealer wholesale finance, vehicle finance, insurance, and related value-added services. Absa currently works with 15 dealerships that stock BYD vehicles across South Africa. Charl Potgieter, managing executive for Absa Vehicle and Asset Finance, said the partnership aligns with the bank's goal of reaching carbon neutrality by 2050 and will help grow its sustainable finance portfolio. 'We recognise the growing demand for energy-efficient mobility solutions,' Potgieter said. Market growth and affordability still a challenge According to Naamsa, NEV sales in South Africa doubled in 2024 year on year, with further growth recorded in the first quarter of 2025. However, affordability and infrastructure remain obstacles to mass adoption. Absa's NEV finance portfolio, comprising both hybrid and electric vehicles, has seen growth off a low base in recent years, reflecting a gradual shift in consumer sentiment. BYD targets wider reach and lower entry point BYD, which sold over 4.2 million NEVs globally in 2024, offers vehicles at lower price points than many competitors. Its models include features such as vehicle-to-load functionality, which allows owners to power household devices from their cars. Steve Chang, general manager of BYD South Africa, said the partnership was based on three core values: affordability, accessibility and sustainability. 'We're introducing models at more competitive prices, expanding through Absa's network, and aiming to reduce emissions with every sale,' he said. Part of broader green strategy Absa said the partnership complements its broader green finance strategy, which includes backing Africa's largest standalone battery facility. The bank recently met its R100bn sustainable finance target a year ahead of schedule and aims to continue scaling up support for low-carbon initiatives.
Zawya
30 minutes ago
- Zawya
African startups take on medicine access gaps with smarter supply chains
A healthcare-focused panel discussion at this year's Sapics Conference in Cape Town spotlighted Africa's emergence as a creator of health supply chain innovations with global potential. The session brought together African entrepreneurs who are working to improve access to medicine, patient safety, and supply chain systems. It was moderated by Stella Kivila, Director of Healthtech Strategy & Impact at Salient Advisory, a firm tracking over 1,000 healthtech start-ups across Africa. 'We are seeing a new generation of African entrepreneurs tackling one of the continent's most pressing problems: fragmented and inefficient medicine supply chains,' said Kivila. The cost of fragmentation Public healthcare distribution systems across Africa are often overburdened, with many consumers relying on fragmented private supply chains. According to Kivila, this can add as much as 60% to the final price of medicines. "Patients are left with little guarantee of quality or availability, and there is a significant risk of counterfeit and substandard products entering the system," she said. Two start-ups – Dawa Mkononi from Tanzania and Meditect from Côte d'Ivoire – shared how they are using technology, data and new models to improve healthcare delivery. Dawa Mkononi: "Medicine in the palm of your hand" Dr Joseph Paul, a medical doctor and software engineer, founded Dawa Mkononi after a pivotal experience in a rural Tanzanian village. "While assisting a mother during childbirth, the essential drug needed to accelerate labour was unavailable. Six hours later, the family returned with a medicine that sadly proved ineffective. It was likely a counterfeit." Paul developed a digital platform and distribution system to deliver safe, verified medicines to pharmacies, clinics and hospitals, supported by inventory management and demand forecasting. In urban areas, delivery takes a few hours. The platform also offers credit financing. "Our mission is to make medicine accessible, affordable and safe, through data-driven supply chains," Paul said. The company has reached over 1,000 pharmacies, served more than 500,000 patients, and facilitated over $1m in credit. It is currently growing fourfold annually. Meditect: Restoring trust in medicines For Dr Arnaud Pourredon, founder of Meditect, the turning point also came from a moment in clinical care. 'I couldn't buy malaria treatment for a three-year-old child. That's when I knew we had to fix the system,' he said. Meditect provides digital tools that support drug traceability, supply chain visibility and pharmacy management, with a focus on Francophone Africa. "By improving access to quality medicine and enhancing transparency, we can increase life expectancy in Africa by 10 years," Pourredon said. The platform supports thousands of healthcare professionals and aims to help leapfrog infrastructure gaps using technology. i3: A new model for supporting innovators Both Dawa Mkononi and Meditect are part of the Investing in Innovation (i3) programme, launched in 2022 to connect African health supply chain innovators with donors, governments and the private sector. The initiative has provided $3m in grant funding to 60 start-ups in 18 countries. Rather than acting as a traditional accelerator, i3 offers tailored support and market access, backed by partners including the Gates Foundation, MSD, Cencora, Endless Foundation, HELP Logistics, and Sanofi's Global Health Unit. "Africa doesn't lack ingenuity. It lacks systems to support and scale it," said Kivila. "That's what we're fixing with i3." Locally led systems for Africa and beyond The panel was part of the 47th annual Sapics Conference, attended by more than 700 supply chain professionals from across Africa and the world. As Kivila concluded: "Africa's healthcare future does not have to be imported. It is being built here – by Africans, for Africans, and increasingly, for the world." All rights reserved. © 2022. Provided by SyndiGate Media Inc. (
Zawya
30 minutes ago
- Zawya
South Africa startup Altera raises $1.5mln for donor cell platform
South African biotech startup Altera Biosciences has raised R29m in pre-seed funding to advance its work on a universal donor cell platform, a breakthrough that could revolutionise treatments for organ rejection, cancer, and diabetes. The raise, led by OneBio Venture Studio and E Squared Investments, is among the largest of its kind in the country and marks a milestone for Africa's nascent cell and gene therapy industry. Founded by Alexandra Miszewski and Professor Michael Pepper, Altera aims to become Africa's first dedicated cell and gene therapy company, targeting global health challenges through gene-silencing technology that eliminates immune rejection in transplants. 'By removing the identity markers on donor cells that trigger immune responses, we're developing off-the-shelf therapies that can work across genetically diverse populations,' said Miszewski. 'This could dramatically improve access and outcomes in transplant medicine and beyond.' Miszewski is an Allan Gray Orbis Foundation Fellow with a track record in biotech ventures, including Regenesis Vet and Novita Biotechnology. She is joined by Professor Pepper, director of the Institute for Cellular and Molecular Medicine at the University of Pretoria and a leading immunology researcher. Professor Pepper said Africa's genetic diversity made it an ideal testbed for scalable therapies. 'We are building from a globally inclusive foundation, which gives our platform broader relevance. Our work starts here, but it's designed for the world.' The company has not yet disclosed which conditions it will target first, citing strategic and IP considerations. The deal is being hailed as a turning point for Africa's biotech sector, with investors increasingly backing the continent's scientific potential.
